Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048782 | 0.93 | PTGS2 (0.33) | CNR1CNR2PTGS2CYP3A4LPL | |
| SCHEMBL15066582 | 0.88 | CNR1 (0.33) | CNR1CNR2PTGS2CYP3A4LPL | |
| SCHEMBL6460367 | 0.84 | PTGS2 (0.48) | PTGS2CYP3A4LPLLIPGALDH1A1 | |
| SCHEMBL27408797 | 0.83 | CSNK2A1 (0.31) | — | |
| SCHEMBL146982 | 0.80 | HPGD (0.48) | PTGS2CYP3A4HTTNPC1HPGD | |
| SCHEMBL27958343 | 0.80 | HSD17B1 (0.30) | — | |
| SCHEMBL1780256 | 0.79 | NOS2 (0.39) | HTTALDH1A1FFAR4 | |
| SCHEMBL8436317 | 0.78 | PTGS2 (0.54) | PTGS2CYP3A4HTTNPC1HPGD | |
| SCHEMBL1777432 | 0.77 | PTGS2 (0.55) | PTGS2CYP3A4LPLLIPGALDH1A1 | |
| SCHEMBL19358155 | 0.77 | PTGS2 (0.55) | PTGS2CYP3A4LPLLIPGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| CN-113260603-B | Preparation of 5-aryl pentanols | 巴斯夫欧洲公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3908566-B1 | PREPARATION OF 5-ARYL PENTANOLS | BASF SE (DE) | 2023-07-26 | — | — | EP | claimed |
| US-11365168-B2 | Preparation of 5-aryl-pentanols | BASF SE (DE) | 2022-06-21 | — | — | US | claimed |
| EP-3908566-A1 | PREPARATION OF 5-ARYL-PENTANOLS | BASF SE (DE) | 2021-11-17 | — | — | EP | claimed |
| CN-113260603-A | Preparation of 5-arylpentanols | 巴斯夫欧洲公司 | 2021-08-13 | — | — | CN | claimed |
| CN-111978953-A | Long-afterglow luminescent composition based on BODIPY luminophor and application | 复旦大学 | 2020-11-24 | — | — | CN | claimed |
| WO-2020144307-A1 | PREPARATION OF 5-ARYL-PENTANOLS | BASF SE (DE) | 2020-07-16 | — | — | WO | claimed |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2019-10-15 | — | — | US | claimed |
| CN-1247492-C | Cobalt catalyst composition for ethylene oligomerization and application thereof | CHINA NAT PETROLEUM CORP (CN) | 2006-03-29 | — | — | CN | claimed |
| WO-2005124453-A2 | PERYLENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | claimed |
| WO-2005044250-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | claimed |
| CN-1202049-C | Iron-based catalyst composition for ethylene oligomerization and application thereof | CHINA NAT PETROLEUM CORP (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-1463799-A | Binuclear iron-based catalyst composition for preparing alpha-olefin by ethylene oligomerization and method for preparing linear alpha-olefin | PETROCHINA CO LTD (CN) | 2003-12-31 | — | — | CN | claimed |
| CN-1463800-A | Binuclear cobalt catalyst composition for synthesizing linear alpha-olefin by ethylene oligomerization and method for preparing linear alpha-olefin | PETROCHINA CO LTD (CN) | 2003-12-31 | — | — | CN | claimed |
| CN-1403424-A | Cobalt catalyst composition for ethylene oligomerization and preparation method of alpha-olefin | CHINA NAT PETROLEUM CORP (CN) | 2003-03-19 | — | — | CN | claimed |
| CN-1374281-A | Iron-based catalyst composition for ethylene oligomerization and preparation method of alpha-olefin | CHINA PETROLEUM CORP (CN) | 2002-10-16 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | CNR1 572/4885CNR2 1058/4885PTGS2 3794/4885 |
| US-11365168-B2 | Preparation of 5-aryl-pentanols | HPD, CYP3A5, HTR3C | CNR1 581/4885CNR2 506/4885PTGS2 362/4885 |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | UBE2L3, COG8, ACSL3 | CNR1 3606/4885CNR2 3896/4885PTGS2 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.